SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Materials, Inc. engages in provision of materials engineering solutions used to produce semiconductors. The firm also focuses on design, development, production, and servicing of the critical wafer fabrication tools used for customers to manufacture semiconductors. It operates through the following segments: Semiconductor Systems and Applied Global Services (AGS). The Semiconductor Systems segment includes designing, development, manufacturing and sale of equipment used to fabricate semiconductor chips referred to as integrated circuits. The AGS segment engages in provision of services, spares, and factory automation software to customer fabrication plants globally. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials is facing significant downward volatility as the market digests broader semiconductor sector rotation and heavy institutional selling, despite the company reporting record revenue and strong AI-driven guidance. While some investors view the pullback as a buying opportunity given the company's central role in the AI infrastructure buildout, the community remains divided, with active debates centered on whether recent price action reflects a structural correction in the AI bubble or a temporary liquidity-driven hunt.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is rallying as institutional investors and high volume suggest a significant accumulation phase, leading the community to discuss a potential short squeeze as the stock breaks through key resistance levels. Traders are increasingly bullish, pointing to the company's strong cash position, profitability, and leadership in the agentic AI and orchestration sector as primary drivers for the sustained upward momentum.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors digest positive commentary regarding manufacturing progress and FDA alignment for its lead candidate, CAN-2409, ahead of a planned BLA submission. The community is actively discussing strong institutional ownership and anticipation for upcoming clinical data presentations at the ASTRO meeting.

TSS, Inc. engages in the provision of comprehensive services for the planning, design, development and maintenance of mission-critical facilities and information infrastructure as well as integration services. It operates through the Facilities and Systems Integration Services business segments. The Facilities segment consists of the design, project management, and maintenance of data center and mission-critical business operations. The Systems Integration segment integrates information technology equipment for original equipment manufacturer vendors and customers to be used inside data center environments, including modular data centers. The company was founded by Gerard J. Gallagher on December 20, 2004 and is headquartered in Georgetown, TX.

TSS Inc

TSS Inc. is facing intense downward pressure following a weak earnings report that disappointed investors with declining revenue, despite some community interest in their pivot toward higher-margin systems integration and long-term data center infrastructure. While bulls are pinning hopes on future rack integration growth and new facility expansions, the community remains deeply divided, with many actively discussing the lack of growth visibility and management's perceived failure to capitalize on the AI infrastructure boom.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is experiencing significant downward pressure as investors express frustration over a prolonged slide and lack of direct communication from management regarding integration progress following recent acquisitions. Despite bearish sentiment, the community remains divided, with long-term supporters pointing to institutional accumulation and the CEO's track record as reasons to maintain positions while others warn of continued volatility tied to macro headwinds and ongoing selling pressure.

Workday, Inc. engages in the development of enterprise cloud applications for finance and human resources. The firm delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. It operates through the Cloud Applications segment. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday stock is trending following reports that private equity firm Silver Lake is in early-stage talks to acquire the company, triggering significant market volatility and multiple trading halts. While the market is buzzing over the potential for a massive leveraged buyout, investors remain divided, with some questioning the feasibility of the rumored valuation and others debating whether this signals a sector-wide recovery for software companies.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu Holdings is facing mixed sentiment as investors weigh strong customer growth and recent strategic expansion against concerns over CFO turnover and broader regional credit risks. While some community members view the current price action as an accumulation opportunity, others are exercising caution ahead of upcoming earnings and monitoring the impact of new leadership on the company's long-term international expansion.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle (CRCL) is experiencing significant upward momentum as investors speculate on the potential passage of the Clarity Act and celebrate recent regulatory wins, including the company's federal trust bank charter. The community is actively tracking the stock's institutional accumulation, with many discussing its long-term potential as essential financial infrastructure for AI-driven payments and real-world assets.

Fundrise Innovation Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is experiencing significant volatility and intense community debate as shareholders react to an accelerated lockup expiration, sparking fears of a potential sell-off. Investors remain polarized, with bulls pointing to the fund's exposure to high-profile AI and space companies like Anthropic and SpaceX as long-term catalysts, while bears warn that the stock continues to trade at a substantial premium to its net asset value.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne is trending as investors highlight its position as the most undervalued pure-play AI cybersecurity stock, often pointing to its robust balance sheet, zero debt, and strategic equity stake in Anthropic as key differentiators. The community is actively debating the company's potential as an acquisition target, drawing favorable comparisons to recent high-valuation takeovers in the sector while contrasting its lower price-to-sales ratio against competitors like CrowdStrike and Palo Alto Networks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of +9.62% and -98.75%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Are Medical Stocks Lagging  Celldex Therapeutics (CLDX) This Year?

Here is how Celldex Therapeutics (CLDX) and Illumina (ILMN) have performed compared to their sector so far this year.

CLDX Stock Down 10% After-Hours — What’s Driving The Selloff?

Equity

Celldex announced that its experimental drug barzolvolimab missed key goals in a mid-stage study for prurigo nodularis. 

Eton Pharmaceuticals (ETON) Moves 13.8% Higher: Will This Strength Last?

Eton Pharmaceuticals (ETON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval?

Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval...

Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of -6.88% and -98.87%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Innoviva (INVA) Tops Q1 Earnings Estimates

Innoviva (INVA) delivered earnings and revenue surprises of +3.53% and -1.83%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High?

The mean of analysts' price targets for Celldex (CLDX) points to a 76.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Pictet Asset Management Holding SA Reduces Holdings in Celldex Therapeutics, Inc. $CLDX

Pictet Asset Management Holding SA reduced its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 20.1% during the fourth quarter, according to the company in its most...

Celldex Therapeutics (NASDAQ:CLDX) Shares Pass Above 200 Day Moving Average - What's Next?

Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above 200-Day Moving Average - Here's Why...

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Celldex Therapeutics Inc.

Extremely Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$42.61
Prev Close	$44.87
Open	$45.13
Dividend Yield	0.00%
50-Day Moving Average	$35.82
Beta	1.14
Avg. Volume	945,264.73
PE Ratio	-10.29

52-Week High	$45.14
52-Week Low	$20.37
Market Capitalization	$3.52B
EPS (Annual)	-$3.90
Price to Book	4.93
Revenue Per Employee	$7,803.03

Feed

News

Sentiment

Earnings

Fundamentals

Info